Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics, has announced that CEO Dr. Deborah Birx will present at the 7th Annual Bacteriophage Therapy Summit in Boston, MA. The presentation is scheduled for Thursday, March 13, 2025, at 9:00am ET.
The company focuses on developing high-purity pathogen-specific bacteriophage therapeutics to address antibiotic-resistant and difficult-to-treat bacterial infections.
Armata Pharmaceuticals (NYSE American: ARMP), una compagnia biotecnologica in fase clinica specializzata in terapie a base di batteriofagi, ha annunciato che il CEO Dr. Deborah Birx presenterà al 7° Summit Annuale sulla Terapia con Batteriofagi a Boston, MA. La presentazione è programmata per giovedì 13 marzo 2025, alle 9:00 ET.
L'azienda si concentra sullo sviluppo di terapie a base di batteriofagi specifici per patogeni ad alta purezza, per affrontare infezioni batteriche resistenti agli antibiotici e difficili da trattare.
Armata Pharmaceuticals (NYSE American: ARMP), una empresa biotecnológica en etapa clínica especializada en terapias con bacteriófagos, ha anunciado que la CEO Dra. Deborah Birx presentará en el 7° Cumbre Anual de Terapia con Bacteriófagos en Boston, MA. La presentación está programada para el jueves 13 de marzo de 2025, a las 9:00 a.m. ET.
La empresa se centra en desarrollar terapias con bacteriófagos específicos para patógenos de alta pureza, para abordar infecciones bacterianas resistentes a los antibióticos y difíciles de tratar.
Armata Pharmaceuticals (NYSE American: ARMP)는 박테리오파지 치료를 전문으로 하는 임상 단계의 생명공학 회사로, CEO인 Deborah Birx 박사가 매사추세츠주 보스턴에서 열리는 제7회 연례 박테리오파지 치료 정상 회담에서 발표할 것이라고 발표했습니다. 발표는 2025년 3월 13일 목요일 오전 9시(ET)로 예정되어 있습니다.
회사는 항생제 내성과 치료가 어려운 세균 감염을 해결하기 위해 고순도 병원체 특이적 박테리오파지 치료제를 개발하는 데 집중하고 있습니다.
Armata Pharmaceuticals (NYSE American: ARMP), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies par bactériophages, a annoncé que la PDG Dr. Deborah Birx fera une présentation lors du 7e Sommet Annuel sur la Thérapie par Bactériophages à Boston, MA. La présentation est prévue pour le jeudi 13 mars 2025, à 9h00 ET.
L'entreprise se concentre sur le développement de thérapies par bactériophages spécifiques aux pathogènes de haute pureté pour traiter les infections bactériennes résistantes aux antibiotiques et difficiles à traiter.
Armata Pharmaceuticals (NYSE American: ARMP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Bakteriophagentherapien spezialisiert hat, hat angekündigt, dass CEO Dr. Deborah Birx auf dem 7. Jahrestreffen zur Bakteriophagentherapie in Boston, MA, präsentieren wird. Die Präsentation ist für Donnerstag, den 13. März 2025, um 9:00 Uhr ET geplant.
Das Unternehmen konzentriert sich auf die Entwicklung von hochreinen, patogen-spezifischen Bakteriophagentherapien zur Bekämpfung von antibiotikaresistenten und schwer zu behandelnden bakteriellen Infektionen.
- None.
- None.
For more information: https://bacteriophage-summit.com/
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic, including in-house phage-specific cGMP manufacturing to support full commercialization.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-the-7th-annual-bacteriophage-therapy-summit-302392599.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
When is Dr. Deborah Birx presenting at the 7th Annual Bacteriophage Therapy Summit for ARMP?
What type of therapeutics is Armata Pharmaceuticals (ARMP) developing?
Where will the 2025 Bacteriophage Therapy Summit featuring ARMP's presentation be held?
What is ARMP's current development stage as a pharmaceutical company?
